| Atorvastatin |
II-9732/31.05.2010 |
Avanor, Film coated tablet, 20, mg, Pack: 30 |
Тева Фармасютикълс България ЕООД, България |
Teva UK Ltd, UK Pharmachemie B.V. Netherlands TEVA Pharmaceutical Works Private Limited Campany, Hungary, TEVA Sante, France TEVA Czech Industries s.r.f., Czech Republic |
11.64 |
2.33 |
13.97 |
6% |
0.7 |
12.34 |
2.47 |
14.81 |
18% |
2.1 |
14.44 |
2.89 |
17.33 |
цената се заличава КЦРР-2552/14.03.2013 |
КЦ-1767/15.09.2010 |
26.10.2010 |
26.10.2010 |
Заличен |
964 |
| Bevacizumab |
EU/1/04/300/002 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-16 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
1787.14 |
357.43 |
2144.57 |
4% |
10 |
1797.14 |
359.43 |
2156.57 |
16% |
25 |
1822.14 |
364.43 |
2186.57 |
|
НСР-6422/12.06.2015. |
26.06.2015 |
26.06.2015 |
Активен |
3222 |
| Bevacizumab |
EU/1/04/ 300/002 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-16 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
1787.14 |
357.43 |
2144.57 |
4% |
10 |
1797.14 |
359.43 |
2156.57 |
16% |
25 |
1822.14 |
364.43 |
2186.57 |
|
НСР-6422/12.06.2015. |
26.06.2015 |
26.06.2015 |
Неактивен |
3222 |
| Bevacizumab |
EU/1/04/300/001 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-4 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
485.65 |
97.13 |
582.78 |
4% |
10 |
495.65 |
99.13 |
594.78 |
16% |
25 |
520.65 |
104.13 |
624.78 |
|
НСР-6421/12.06.2015. |
26.06.2015 |
26.06.2015 |
Активен |
3221 |
| Bevacizumab |
EU/1/04/ 300/001 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-4 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
485.65 |
97.13 |
582.78 |
4% |
10 |
495.65 |
99.13 |
594.78 |
16% |
25 |
520.65 |
104.13 |
624.78 |
|
НСР-6421/12.06.2015. |
26.06.2015 |
26.06.2015 |
Неактивен |
3221 |
| Bevacizumab |
EU/1/04/ 300/002 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-16 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
1787.14 |
357.43 |
2144.57 |
4% |
10 |
1797.14 |
359.43 |
2156.57 |
16% |
25 |
1822.14 |
364.43 |
2186.57 |
|
НСР-6422/12.06.2015. |
26.06.2015 |
26.06.2015 |
Неактивен |
3222 |
| Bevacizumab |
EU/1/04/ 300/001 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-4 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
485.65 |
97.13 |
582.78 |
4% |
10 |
495.65 |
99.13 |
594.78 |
16% |
25 |
520.65 |
104.13 |
624.78 |
|
НСР-6421/12.06.2015. |
26.06.2015 |
26.06.2015 |
Неактивен |
3221 |
| Bevacizumab |
EU/1/04/300/002 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-16 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
1921.66 |
384.33 |
2305.99 |
4% |
10 |
1931.66 |
386.33 |
2317.99 |
16% |
25 |
1956.66 |
391.33 |
2347.99 |
|
НСР-4815/13.10.2014 |
27.10.2014 |
27.10.2014 |
Неактивен |
3222 |
| Bevacizumab |
EU/1/04/300/001 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-4 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
522.21 |
104.44 |
626.65 |
4% |
10 |
532.21 |
106.44 |
638.65 |
16% |
25 |
557.21 |
111.44 |
668.65 |
|
НСР-4816/13.10.2014 |
27.10.2014 |
27.10.2014 |
Неактивен |
3221 |
| Bevacizumab |
EU/1/04/300/001 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-4 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
543.97 |
108.79 |
652.76 |
4% |
10 |
553.97 |
110.79 |
664.76 |
16% |
25 |
578.97 |
115.79 |
694.76 |
корекц. НСР-2917/07.03.2014 |
НСР-2317/13.01.2014 |
14.02.2014 |
14.02.2014 |
Неактивен |
3221 |
| Bevacizumab |
EU/1/04/300/002 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-16 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
2001.71 |
400.34 |
2402.05 |
4% |
10 |
2011.71 |
402.34 |
2414.05 |
16% |
25 |
2036.71 |
407.34 |
2444.05 |
корекц. НСР-2917/07.03.2014 |
НСР-2316/13.01.2014 |
14.02.2014 |
14.02.2014 |
Неактивен |
3222 |
| Bevacizumab |
EU/1/04/300/001 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-4 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
560.5 |
112.1 |
672.6 |
4% |
10 |
570.5 |
114.1 |
684.6 |
16% |
25 |
595.5 |
119.1 |
714.6 |
|
КЦРР-2732/20.03.2013 |
18.04.2013 |
18.04.2013 |
Неактивен |
3221 |
| Bevacizumab |
EU/1/04/300/002 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-16 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
2129.49 |
425.9 |
2555.39 |
4% |
10 |
2139.49 |
427.9 |
2567.39 |
16% |
25 |
2164.49 |
432.9 |
2597.39 |
|
КЦРР-2800/20.03.2013 |
18.04.2013 |
18.04.2013 |
Неактивен |
3222 |
| Bevacizumab |
EU/1/04/300/002 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-16 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
2148.93 |
429.79 |
2578.72 |
4% |
10 |
2158.93 |
431.79 |
2590.72 |
16% |
25 |
2183.93 |
436.79 |
2620.72 |
|
КЦРР-923/04.07.2012 |
19.07.2012 |
19.07.2012 |
Неактивен |
3222 |
| Bevacizumab |
EU/1/04/300/001 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-4 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
587.69 |
117.54 |
705.23 |
4% |
10 |
597.69 |
119.54 |
717.23 |
16% |
25 |
622.69 |
124.54 |
747.23 |
|
КЦРР-845/15.06.2012 |
03.07.2012 |
03.07.2012 |
Неактивен |
3221 |
| Bevacizumab |
EU/1/04/300/002 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-16 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
2358.2 |
471.64 |
2829.84 |
6% |
15 |
2373.2 |
474.64 |
2847.84 |
18% |
30 |
2403.2 |
480.64 |
2883.84 |
|
КЦ-529/13.02.2009 |
02.03.2009 |
02.03.2009 |
Неактивен |
3222 |
| Bevacizumab |
EU/1/04/300/001 |
Avastin, Concentrate for solution for infusion, 25 mg/ml-4 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
648.36 |
129.67 |
778.03 |
6% |
15 |
663.36 |
132.67 |
796.03 |
18% |
30 |
693.36 |
138.67 |
832.03 |
|
КЦ-529/13.02.2009 |
02.03.2009 |
02.03.2009 |
Неактивен |
3221 |
| Hepatitis A, inactivated, whole virus |
II-1955/18.04.2008 |
AVAXIM 160 IU Adult, Suspension for injection, 0.5 ml, -, Pack: 1 pre-filled syringe |
Sanofi Pasteur S.A., Франция |
Sanofi Pasteur S.A., France; Sanofi-Aventis, Унгария |
34.79 |
6.96 |
41.75 |
4% |
1.39 |
36.18 |
7.24 |
43.42 |
16% |
5.57 |
41.75 |
8.35 |
50.1 |
промяна на обстоятелства НСР-5423/16.01.2015 |
КЦРР-2044/24.01.2013 |
28.03.2013 |
28.03.2013 |
Неактивен |
1718 |
| Hepatitis A, inactivated, whole virus |
9800052 |
AVAXIM 160 U adult, susp. Inj. Pre-filled syringe 0, 5 ml, Хепатит А вирус, щам GBM, инактивиран и адсорбиран ….. 160 единици, ml, Pack: 1 |
Sanofi Pasteur S.A., Франция |
Sanofi Pasteur S.A., France; Sanofi-Aventis, Унгария |
34.79 |
6.96 |
41.75 |
4% |
1.39 |
36.18 |
7.24 |
43.42 |
16% |
5.57 |
41.75 |
8.35 |
50.1 |
промяна на обстоятелства НСР-5423/16.01.2015 |
КЦРР-2044/24.01.2013; НСР-9461/01.06.2016 |
02.07.2016 |
02.07.2016 |
Заличен |
1718 |
| Hepatitis A, inactivated, whole virus |
II-1955/18.04.2008 |
AVAXIM 160 U adult, susp. Inj. Pre-filled syringe 0, 5 ml, Хепатит А вирус, щам GBM, инактивиран и адсорбиран ….. 160 единици, ml, Pack: 1 |
Sanofi Pasteur S.A., Франция |
Sanofi Pasteur S.A., France |
46.16 |
9.23 |
55.39 |
4% |
1.85 |
48.01 |
9.6 |
57.61 |
16% |
7.39 |
55.4 |
11.08 |
66.48 |
|
КЦ-723/16.03.2009 |
03.04.2009 |
03.04.2009 |
Неактивен |
1718 |
| Hepatitis A, inactivated, whole virus |
20060246 |
AVAXIM 80 IU Pediatric, Suspension for injection, 0.5 ml, -, Pack: 1 pre-filled syringe |
Sanofi Pasteur S.A., Франция |
Sanofi Pasteur S.A., France; Sanofi-Aventis, Унгария |
22.8 |
4.56 |
27.36 |
6% |
1.37 |
24.17 |
4.83 |
29 |
18% |
4.1 |
28.27 |
5.65 |
33.92 |
промяна на обстоятелства НСР-5497/23.01.2015 |
КЦРР-2044/24.01.2013 |
28.03.2013 |
28.03.2013 |
Неактивен |
1717 |
| Hepatitis A, inactivated, whole virus |
20060246 |
AVAXIM 80 U pediatric, susp. Inj. Pre-filled syringe 0, 5 ml, Inactivated Hepatitis A virus / (strain GMB) / 80 U, ml, Pack: 1 |
Sanofi Pasteur S.A., Франция |
Sanofi Pasteur S.A., France; Sanofi-Aventis, Унгария |
22.8 |
4.56 |
27.36 |
6% |
1.37 |
24.17 |
4.83 |
29 |
18% |
4.1 |
28.27 |
5.65 |
33.92 |
промяна на обстоятелства НСР-5497/23.01.2015 |
КЦРР-2044/24.01.2013; НСР-9460/01.06.2016 |
02.07.2016 |
02.07.2016 |
Заличен |
1717 |
| Hepatitis A, inactivated, whole virus |
II-13178/25.05.2006 г. |
AVAXIM 80 U pediatric, susp. Inj. Pre-filled syringe 0, 5 ml, Inactivated Hepatitis A virus / (strain GMB) / 80 U, ml, Pack: 1 |
Sanofi Pasteur S.A., Франция |
Sanofi Pasteur S.A., France |
31.29 |
6.26 |
37.55 |
4% |
1.25 |
32.54 |
6.51 |
39.05 |
16% |
5.01 |
37.55 |
7.51 |
45.06 |
|
КЦ-723/16.03.2009 |
03.04.2009 |
03.04.2009 |
Неактивен |
1717 |
| Moxifloxacin |
20000430 |
AVELOX, Film coated tablet, 400, mg, Pack: 7 |
Bayer Pharma AG, Германия |
Bayer Pharma AG, Germany |
28.77 |
5.75 |
34.52 |
6% |
1.73 |
30.5 |
6.1 |
36.6 |
18% |
5.18 |
35.68 |
7.14 |
42.82 |
корекционно решение НСР-6748/16.07.2015; цената е вписана в регистъра на пределните цени с решение НСР-8644/31.03.2016 (в сила от 02.05.2016) |
НСР-6371/03.06.2015. |
18.06.2015 |
18.06.2015 |
Заличен |
2623 |
| Moxifloxacin |
20000430 |
AVELOX, Film coated tablet, 400, mg, Pack: 7 |
Bayer Pharma AG, Германия |
Bayer Pharma AG, Germany |
32.51 |
6.5 |
39.01 |
4% |
1.3 |
33.81 |
6.76 |
40.57 |
16% |
5.2 |
39.01 |
7.8 |
46.81 |
промяна на обстоятелства НСР-3344/24.04.2014 |
НСР-3037/21.03.2014 |
09.04.2014 |
09.04.2014 |
Неактивен |
2623 |